semaglutide swisschems Swissmedic issues warning against falsified and misleading “GLP-1” weight loss products SEMAGLUTIDE

Are seeking clinically proven weight loss support with an FDA-approved medication

It is therefore in this context, where treatment options for obesity remain very limited, that the appearance of Ozempic and Mounjaro on the market is currently generating enormous interest, both in the medical and scientific communities and in the general population

Some patients report: Aching in the knees, hips, shoulders, hands, or ankles Generalized stiffness or body aches Muscle soreness or weakness Pain that appears after a dose increase Changes in an existing arthritis condition Discomfort after becoming more physically active A symptom beginning after someone starts tirzepatide may suggest a possible connection, but timing alone cannot prove that the medication caused it

Schedule regular appointments to assess glycemic control (through A1C testing), weight changes, and tolerability